TROP2 expression (Trophoblast cell-surface antigen 2)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-TROP2-EXPRESSION |
|---|---|
| Type | Biomarker |
| Aliases | EGP-1GA733-1TACSTD2TROP2 expressionЕкспресія TROP2 (трофобластний поверхневий антиген 2) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ASCENT-BARDIA-2021 SRC-NCCN-BLADDER-2025 SRC-NCCN-BREAST-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC (TROP2 antibody — clones SP295 / EPR20043 / MOR-T2). Scoring not standardized for clinical decision; ASCENT/TROPiCS-02 enrolled biomarker-unselected populations and showed benefit independent of TROP2 expression level. Unitscategorical (positive | negative) — informational only; no validated clinical cutoff for sacituzumab eligibility |
| Related biomarkers | None declared |
Notes
Informational marker for sacituzumab govitecan ADC therapy. Existing regimens (REG-SACITUZUMAB-TNBC for ASCENT 2L+ mTNBC; sacituzumab in urothelial post-platinum/IO via TROPHY-U-01) do not require TROP2 testing for eligibility — broad epithelial expression and pivotal-trial design (biomarker-unselected) make IHC explanatory rather than gating. Documented here so render layer can surface "TROP2-directed ADC" rationale for clinicians without introducing a false gate. No new indication or regimen entity in this chunk — sacituzumab regimens already exist.
Used By
Indications
IND-NSCLC-2L-DATO-DXD- IND-NSCLC-2L-DATO-DXD